Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Roche Holding Ltd.    RHO5   CH0012032048

News SummaryMost relevantAll newsSector newsTweets 
Latest news on ROCHE HOLDING LTD.
04/21 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – COO Sold 4,405 shares of Sto..
04/20 CHUGAI PHARMACEUTICAL : Reports Summarize Immunoglobulins Study Results from Chu..
04/20ROCHE HOLDING LTD. : quaterly sales release
04/20 REMINDER : Invitation to Roche’s First Quarter Sales 2017 Conference Call
04/19 ROCHE : FDA Grants Genentech's Tecentriq (Atezolizumab) Accelerated Approval as ..
04/19 ROCHE : Genentech Announces Positive Interim Results for Emicizumab in Phase III..
04/19 ROCHE : Genentech`s Tecentriq receives FDA-accelerated approval for advanced bla..
04/19 ROCHE : FDA grants Roche's TECENTRIQ® (atezolizumab) accelerated approval as ini..
04/19 ROCHE : FDA approves Roche's Lucentis (ranibizumab injection) for diabetic retin..
04/19 ROCHE : to present new data at AAN reinforcing efficacy and safety of newly FDA-..
04/19 GENENTECH : to Present New Data at AAN Reinforcing Efficacy and Safety of Newly ..
04/18 ROCHE : FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic..
04/18 ROCHE : FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval ..
04/18 ROCHE : Genentech Reports Positive Interim Results On Emicizumab
04/18 ROCHE : Wisconsin Ag in the Classroom Awards Grants to Fund Ag Literacy Projects
04/18 ROCHE : FDA Grants Genentech’s TECENTRIQ (Atezolizumab) Accelerated Approv..
04/17 ROCHE : FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diab..
04/17 ROCHE : announces positive interim results for emicizumab in phase III study of ..
04/17 GENENTECH : Announces Positive Interim Results for Emicizumab in Phase III Study..
04/15 ROCHE : Thank You National Sponsors of Walk MS
04/15 BRISTOL MYERS SQUIBB : Myers offloads anti-tau, DMD assets to Biogen, Roche for ..
04/14 Roche, Biogen handing over $470M in cash to bag two drug programs from Bristo..
04/13 CHUGAI PHARMACEUTICAL : New Findings in Science Described from Chugai Pharmaceut..
04/13 FOUNDATION MEDICINE, INC. (NASDAQ : FMI) Files An 8-K Departure of Directors or ..
04/13 FOUNDATION MEDICINE, INC. : Change in Directors or Principal Officers (form 8-K)
04/12 ROCHE : SMC u-turn backs Roches Kadcyla for breast cancer
04/11 CHUGAI PHARMACEUTICAL : Alecensa Met Its Primary Endpoint in the ALEX StudyFollo..
04/11 ROCHE : Phase III Study Shows Genentech's Alecensa Was Superior to Crizotinib in..
04/11 ROCHE : takes on Pfizer with new lung cancer data
04/11 ROCHE : Roches Alecensa beats Pfizers Xalkori in lung cancer trial
04/11 ROCHE : s lung cancer drug beats Pfizer rival in study
04/11 ROCHE : Genentech Says Phase III ALEX Study Meets Primary End Point
04/10 ROCHE : Phase III study shows Roche's Alecensa was superior to crizotinib in a s..
04/10 ROCHE : Medicines wholesaler Roche Latvija posts EUR 30.018 million in sales in ..
04/10 ROCHE : Phase III study shows Roche’s Alecensa was superior to crizotinib ..
04/10 ROCHE : Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizot..
04/08 ROCHE : Commission Approves Enhancement of Community Solar in Tucson
04/07 ROCHE : Construction materials and associated items
04/06 Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine's M..
04/06 CHUGAI PHARMACEUTICAL : Establishment of 'AYA's Life,' a Website for Cancer Pati..
04/06 CURIS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/05 CHUGAI PHARMACEUTICAL : Using Multidisciplinary SNS for Outpatient Cancer Treatm..
04/05 CHUGAI PHARMACEUTICAL : A First Approach in the Japanese Pharmaceutical Industry..
04/05 IMPROVING CONSISTENCY IN THE DIAGNOS : Roche CINtec Histology test receives FDA ..
04/05 ROCHE : Prothena pushes Roche-partnered Parkinson`s drug into phase 2 after init..
04/05 IMPROVING CONSISTENCY IN THE DIAGNOS : Roche CINtec Histology test receives FDA ..
04/03 ROCHE : Phase III ALUR study supports the use of Roche's Alecensa for people wit..
04/03 ROCHE : launches cobas Liat PCR System with four assays into CE-markets
04/03 ROCHE : Phase III ALUR study supports the use of Roche’s Alecensa for peop..
04/01 Pharma`s most-valuable brands? J&J, Pfizer and Merck. Valeant, not so much
03/31 ROCHE : FDA approves first drug for aggressive multiple sclerosis
03/31 ROCHE : Patients to Get Free Breast Cancer Drugs
03/31 China Opens to Overseas New Drugs
03/30 ROCHE : Invitation to Roche’s First Quarter Sales 2017 Conference Call
03/30 ROCHE : FDA advisory committee unanimously recommends approval of Roche’s ..
03/29 ROCHE : FDA Advisory Committee Unanimously Recommends Approval of Genentech&rsqu..
03/29 ROCHE : FDA Approves Genentech's OCREVUS (Ocrelizumab) For Relapsing and Primary..
03/29 ROCHE : FDA approves Roche's OCREVUS™ (ocrelizumab) for relapsing and prim..
03/29 ROCHE : FDA approves Roche’s OCREVUS™ (ocrelizumab) for relapsing an..
03/29 ROCHE : FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsin..
03/28 ROCHE : announces launch of cobas HPV on the cobas 6800/8800 Systems for cervica..
03/28 ROCHE : Addressing Threat Of Zika Virus To US Blood Supply
03/27 ROCHE : Health and Human Services Department (HHS); Food and Drug Administration..
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/27 ROCHE : Dying patients want easier access to experimental drugs
03/25 ROCHE : Rituxan For Pemphigus Vulgaris Gets Breakthrough Therapy Designation
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 ROCHE : FDA grants breakthrough therapy designation for MabThera/Rituxan (rituxi..
03/24 ROCHE : FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in ..
03/24 ROCHE : Congresswoman Speier to host "When I Grow Up..." for Elementary and Midd..
03/24 ROCHE : Rep. Speier to Host 'When I Grow Up...' for Elementary and Middle School..
03/22 ROCHE : Global Calcitriol (CAS 32222-06-3) Market- Roche, Sun Pharmaceutical Ind..
03/22 ROCHE : Westminster slips by Vulcans, 5-4
03/22 ROCHE : Oxford Preparatory Academy Sues Its Founder for Allegedly Diverting Fund..
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2017 53 106 M
EBIT 2017 18 532 M
Net income 2017 11 477 M
Debt 2017 8 747 M
Yield 2017 3,41%
P/E ratio 2017 18,54
P/E ratio 2018 16,93
EV / Sales 2017 4,25x
EV / Sales 2018 3,92x
Capitalization 216 757 M
More Financials
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | RHO5 | CH0012032048 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 285  CHF
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.8.78%217 624
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.88%200 330
NOVARTIS AG-1.15%192 857
MERCK & CO., INC.5.13%169 673
More Results